Our Company

Board of Directors

Providing a strategic vision for the future.

  • Douglas M. Fambrough, III Ph.D.

    Chief Executive Officer

    Douglas M. Fambrough, III Ph.D. co-founded Dicerna in 2007 and has served as the Company’s chief executive officer since 2010. Prior to joining Dicerna as CEO, Doug specialized in financing innovative life science technology companies as a general partner with Oxford Bioscience Partners, a Boston-based venture capital firm.

    In 2003, Doug and two other investors founded Sirna Therapeutics, a first-generation RNA interference (RNAi) pioneer; he served on Sirna’s Board of Directors until the company was acquired by Merck for $1.1 billion in 2006. Other investments include Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, Doug was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).

    Doug graduated from Cornell University and obtained his Ph.D. in genetics at the University of California, Berkeley.

  • Martin Freed, M.D.

    Independent Director

    Martin Freed, M.D., has been a member of the Dicerna board of directors since 2016. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015.

    He co-founded and served as chief medical officer of Civitas Therapeutics, Inc., from December 2010 to October 2014 (acquired by Acorda Therapeutics, Inc., or Acorda) and as senior vice president, clinical development of Acorda from October 2014 through January 2015.

    In addition, Dr. Freed has served as chief medical officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology and development strategy and preclinical development for multiple pharmaceutical companies throughout his career. These companies include Avila Therapeutics, Inc., Taligen Therapeutics, Adnexus Therapeutics, Inc.,(acquired by Bristol-Myers Squibb), and Vitae Pharmaceuticals, Inc.

    Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals or SmithKline Beecham, where he served numerous roles including vice president, clinical development and medical affairs in the metabolism therapeutic area. He has authored over 100 publications or presentations.

    Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital. A Fellow of the American College of Physicians, Dr. Freed received his B.S. with Distinction in Biology from the University of Delaware and M.D. from Pennsylvania State University’s College of Medicine.

  • Brian Halak, Ph.D.

    Partner, Domain Associates

    Brian Halak, Ph.D. joined Domain in 2001 and became a partner in 2006. From 2000 to 2001, he was an associate with Advanced Technology Ventures, where he participated in the firm’s investments in Plexxikon, Percardia and Emphasys. Previously, Brian was a consultant at the Wilkerson Group, where he developed strategy for pharmaceutical and medical device companies.

    Brian is currently a member of the Investment Advisory Council for Ben Franklin Technology Partners and BioAdvance, both of which are seed-stage investment groups in Philadelphia.

    Brian holds a Ph.D. in immunology from Thomas Jefferson University and a B.S. in engineering from the University of Pennsylvania.

  • Stephen Hoffman, M.D., Ph.D.

    Senior Advisor, PDL BioPharma

    Stephen Hoffman, M.D., Ph.D. has been a senior advisor to PDL BioPharma since February 2014. Previously, he served as a managing director at Skyline Ventures from May 2007 until February 2014. From January 2003 to March 2007, Stephen was a general partner at TVM Capital. Prior to that, he served as president, chief executive officer and a director of Allos Therapeutics from 1994 to 2002, where he remained as chairman of the board until 2012.

    Stephen was the scientific founder of Somatogen, which was acquired by Baxter in 1998; he held the position of vice president of science and technology at Somatagen from 1987 until 1990.

    In addition to Dicerna, Stephen serves on the board of directors of Genocea Biosciences. Previously, he served on the board of directors of Allos Therapeutics, which was acquired by Spectrum Pharmaceuticals in 2012, and Sirtris Pharmaceuticals, which was acquired by GlaxoSmithKline in 2008.

    Stephen holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine. He completed a fellowship in clinical oncology and a residency and immunodermatology fellowship in dermatology, all at the University of Colorado.

  • Peter Kolchinsky, Ph.D.

    Partner, RA Capital

    Peter Kolchinsky, Ph.D. is a co-founder and general partner of RA Capital Management, which has been investing in healthcare companies since 2002. He has served as a member of the National Academies Board on Global Science and Technology, authored an e-book titled, “The Entrepreneur’s Guide to a Biotech Startup,” and serves as an advisor to startup companies and non-profits.

    Peter received his undergraduate degree in biology from Cornell University and a Ph.D. in virology from Harvard University, where he conducted research at Dana-Farber Cancer Institute on the entry mechanism of the human immunodeficiency virus (HIV).

  • Adam Koppel, M.D., Ph.D.

    Managing Director, Bain Capital

    Adam M. Koppel, M.D., Ph.D., has been a member of the Dicerna board of directors since April 2017. Dr. Koppel rejoined Bain Capital in 2016 as Managing Director of the Bain Capital Life Sciences Fund. He had initially joined Bain Capital Public Equity in 2003 where he was a leader within the healthcare sector until mid-2014.

    During the period mid-2014 to mid-2016, Dr. Koppel was at Biogen where he served as EVP of Corporate Development and Chief Strategy Officer. Other than Dicerna, he sits on the board of directors of Solid Biosciences, PTC Therapeutics (NASD: PTCT) and Trevena (NASD: TRVN).

    Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey & Co in New Jersey where he served a variety of healthcare companies.

    Dr. Koppel received an M.D. and Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with a AB and AM in History and Science.

  • Dennis Langer, M.D., J.D.

    Director, Dicerna Pharmaceuticals

    Dennis Langer, M.D., J.D. has been a director of Dicerna Pharmaceuticals since 2007 and of Myriad Genetics since 2004. He was previously senior vice president in research and development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle.

    He is also a clinical professor in the Department of Psychiatry at Georgetown University School of Medicine.

    Dennis holds a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine and a B.A. in biology from Columbia University.

  • David M. Madden

    Chairman of the Board of Directors Dicerna Pharmaceuticals Founder and Principal, Narrow River Management

    David Madden has been chairman of the board of directors of Dicerna Pharmaceuticals since 2009. He is a founder and principal with Narrow River Management, LP, an investment management company with a focus on equity investments in the emerging pharmaceutical industry.

    From 2000 to 2003, David was co-CEO of Royalty Pharma AG, a private investment management firm specializing in the acquisition of royalty interests in pharmaceutical products. Prior to that position, he was a managing member of Pharmaceutical Partners, LLC, and was president, CEO and a director of Selectide Corporation, a development-stage pharmaceutical company, which was acquired by Marion Merrill Dow in 1995. Additionally, David serves as chairman of the board of Adolor Corporation, and is a member of the board of directors of the Hospital for Special Surgery in New York City.

    David holds a B.S. in electrical engineering from Union College and an M.B.A. from Columbia University.

  • Bruce Peacock

    Director, Dicerna Pharmaceuticals

    Bruce Peacock has served as a member of our board of directors since September 2014. Mr. Peacock served as Chief Financial and Business Officer of Ophthotech Corporation from August 2013 to September 2014 and served as its Chief Business Officer from September 2010 to August 2013.

    From April 2008 to February 2011, Mr. Peacock served as President, Chief Executive Officer and co-Chairman of the board of directors of Alba Therapeutics where he continues to serve as co-Chairman of the board of directors.  Additionally, Mr. Peacock has served as a venture partner of SV Life Sciences Advisors, LLC since 2006.  Previously Mr. Peacock served as the Chief Executive Officer and Director of The Little Clinic; President, Chief Executive Officer and Director of Adolor Corp. (NASDAQ: ADLR) (acquired by Cubist Pharmaceuticals, Inc. (NASDAQ: CBST)); President, Chief Executive Officer and Director of Orthovita, Inc. (acquired by Stryker Corporation); Executive Vice President, Chief Operating Officer and Director of Cephalon, Inc. (acquired by Teva Pharmaceutical Industries Ltd.); and as Chief Financial Officer of Centocor, Inc. (acquired by Johnson & Johnson (NYSE: JNJ).